Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS-mutant Non-small Cell Lung Cancer (NSCLC)”

78 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 78 results

Testing effectiveness (Phase 2)Temporarily pausedNCT07639242
What this trial is testing

Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC

Who this might be right for
Lung CancerLung Cancer (NSCLC)Locally Advanced NSCLC+1 more
UNC Lineberger Comprehensive Cancer Center 60
Testing effectiveness (Phase 2)WithdrawnNCT05815186
What this trial is testing

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

Who this might be right for
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
NYU Langone Health
Testing effectiveness (Phase 2)Ended earlyNCT03095612
What this trial is testing

Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
University of Texas Southwestern Medical Center 41
Testing effectiveness (Phase 2)Ended earlyNCT06024174
What this trial is testing

BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumors
Bristol-Myers Squibb 5
Testing effectiveness (Phase 2)Ended earlyNCT06333678
What this trial is testing

A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center 10
Testing effectiveness (Phase 2)Study completedNCT05002270
What this trial is testing

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

Who this might be right for
Advanced Solid TumorNSCLCCRC
Jacobio Pharmaceuticals Co., Ltd. 29
Early research (Phase 1)Study completedNCT03170206
What this trial is testing

Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Dana-Farber Cancer Institute 34
Testing effectiveness (Phase 2)Study completedNCT04735068
What this trial is testing

Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerKRAS Mutation-Related Tumors
Abramson Cancer Center at Penn Medicine 9
Early research (Phase 1)Study completedNCT04967079
What this trial is testing

Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

Who this might be right for
Non Small Cell Lung Cancer
Shanghai Chest Hospital 33
Testing effectiveness (Phase 2)WithdrawnNCT03004105
What this trial is testing

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Malignant Neoplasm of Respiratory and Intrathoracic Organ CarcinomaAdvanced Lung CancerRecurrent Nonsmall Cell Lung Cancer
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06456138
What this trial is testing

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Who this might be right for
KRAS Mutation-Related TumorsAdvanced Lung CancerRefractory Tumor
Shanghai Chest Hospital 60
Early research (Phase 1)Ended earlyNCT01912625
What this trial is testing

Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Who this might be right for
Recurrent Lung Non-Small Cell CarcinomaStage III Lung Non-Small Cell Cancer AJCC v7Stage IIIA Lung Non-Small Cell Cancer AJCC v7+1 more
National Cancer Institute (NCI) 16
Testing effectiveness (Phase 2)Study completedNCT04620330
What this trial is testing

Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerKRAS Activating Mutation
Verastem, Inc. 90
Early research (Phase 1)Not Yet RecruitingNCT07624214
What this trial is testing

Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)+1 more
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. 198
Early research (Phase 1)Looking for participantsNCT07458347
What this trial is testing

Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

Who this might be right for
KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc. 145
Testing effectiveness (Phase 2)UnknownNCT05451056
What this trial is testing

An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib

Who this might be right for
Non Small Cell Lung Cancer
Yonsei University 37
Testing effectiveness (Phase 2)Study completedNCT02039336
What this trial is testing

Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC

Who this might be right for
Colorectal Cancer
The Netherlands Cancer Institute 35
Early research (Phase 1)Looking for participantsNCT05815173
What this trial is testing

Ladarixin With Sotorasib in Advanced NSCLC

Who this might be right for
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
NYU Langone Health 40
Testing effectiveness (Phase 2)Study completedNCT01951690
What this trial is testing

Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerLung Cancer
Verastem, Inc. 55
Early research (Phase 1)Looking for participantsNCT06586515
What this trial is testing

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Who this might be right for
Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerColorectal Cancer
Eli Lilly and Company 630
Next Page